LGD-4033 was well tolerated. There were no drug-related serious adverse events. Frequency of adverse events was similar between active and placebo groups. Hemoglobin, prostate-specific antigen, aspartate aminotransferase, alanine aminotransferase, or QT intervals did not change significantly at any dose. LGD-4033 had a long elimination half-life and dose-proportional accumulation upon multiple dosing. LGD-4033 administration was associated with dose-dependent suppression of total testosterone, sex hormone–binding globulin, high density lipoprotein cholesterol, and triglyceride levels. follicle-stimulating hormone and free testosterone showed significant suppression at 1.0-mg dose only. Lean body mass increased dose dependently, but fat mass did not change significantly. Hormone levels and lipids returned to baseline after treatment discontinuation.
LGD 3033
$1,680.00 – $11,800.00
LGD-4033 was well tolerated. There were no drug-related serious adverse events. Frequency of adverse events was similar between active and placebo groups. Hemoglobin, prostate-specific antigen, aspartate aminotransferase, alanine aminotransferase.
SKU: N/A
Category: SARMS
Related products
SARMS
$2,600.00 – $16,700.00
SARMS
$300.00 – $2,060.00
SARMS
$1,800.00 – $13,450.00
SARMS
$1,655.00 – $12,200.00
SARMS
$1,200.00 – $7,800.00
SARMS
$1,650.00 – $11,800.00
SARMS
$400.00 – $2,800.00
SARMS
$600.00 – $4,100.00
Be the first to review “LGD 3033”